4-[2-(2,2,2-Trifluoroethyl)guanidino]-2-methanesulphonylpyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-[2-(2,2,2-Trifluoroethyl)guanidino]-2-methanesulphonylpyrimidine
• 英文别名: 4-[2-(2,2,2-trifluoroethyl)guanidino]-2-methylsulphonylpyrimidine；1-(2-methylsulfonylpyrimidin-4-yl)-2-(2,2,2-trifluoroethyl)guanidine
• 化学式: C₈H₁₀F₃N₅O₂S
• 分子量: 297.261
• InChiKey: VAAANURXBCRIGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  119
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-[2-(2,2,2-Trifluoroethyl)guanidino]-2-methanesulphonylpyrimidine 、 3-氨基-1-丙醇 、 sodium;hydride 在 氩 、 溶剂黄146 、 乙醚 作用下， 以 叔丁醇 为溶剂， 反应 6.0h， 以to give 4-[2-(2,2,2-trifluoroethyl)guanidino]-2-(3-aminopropyloxy)pyrimidine (0.07 g.) which的产率得到4-[2-(2,2,2-trifluoroethyl)-guanidino]-2-(3-aminopropyloxy)pyrimidine
  参考文献：
  名称：

  Haloguanidine intermediates

  摘要：

  具有以下式子（I）的化合物可用于抑制胃酸分泌和治疗由胃酸引起或加重的消化性溃疡：##STR1## 其中R.sup.1和R.sup.2为H，C.sub.1-10烷基，C.sub.3-8环烷基或环烷基烷基，其中烷基部分为C.sub.1-6，环烷基部分为C.sub.3-8，每个烷基，环烷基和环烷基烷基可选择地被一个或多个卤素（F，Cl和Br）取代，但至少R.sup.1和R.sup.2中的一个是取代了卤素的烷基，环烷基或环烷基烷基，并且直接连接到氮的碳上没有卤素取代物; X，m，Y，n和R.sup.3如说明书中所述;以及其药学上可接受的酸加成盐。还描述了制备式（I）化合物的方法，包含它们的制药组合物，使用这种组合物的方法以及用于合成式（I）化合物的中间体。

  公开号：

  US04604465A1
• 作为产物：
  描述：

  4-[2-(2,2,2-trifluoroethyl)guanidino]-2-methylthiopyrimidine 、 sodium sulfite 在 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 氯仿 、 水 为溶剂， 生成 4-[2-(2,2,2-Trifluoroethyl)guanidino]-2-methanesulphonylpyrimidine
  参考文献：
  名称：

  Heterocyclic derivatives

  摘要：

  本发明涉及异噁唑衍生物，它们是组胺H-2拮抗剂，能抑制胃酸分泌。根据本发明，提供了一种式I的胍基衍生物：##STR1## 其中R.sup.1和R.sup.2，相同或不同，为氢或1-10C烷基，3-8C环烷基，4-14C环烷基烷基，每个烷基、环烷基或环烷基烷基可选地携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个是卤素取代的，或者R.sup.2是氢而R.sup.1是R.sup.5-E-W-，其中W是2-6烷基烯，可选地被1或2个1-4C烷基取代，E是O、S、SO、SO.sub.2或NR.sup.6，其中R.sup.6是H或1-6C烷基，R.sup.5是H或1-6C烷基，可选地被1或2个1-4C烷基取代，或者R.sup.5和R.sup.6连接形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环；环X是规范中定义的杂环；A是苯基或5-7C环烷基，或者一个可选地插入一到两个基团的1-8C烷基；R.sup.3和R.sup.4是规范中描述的各种基团；以及其药用可接受的酸盐。还描述了制造工艺和药物组合物。

  公开号：

  US04795755A1

文献信息

• Alcohol derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US04451463A1

  公开（公告）日：1984-05-29

  This invention relates to alcohol derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I: ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen-substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.5 --E--W-- in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyl, E is O, S, SO, SO.sub.2 or NR.sup.6 in which R.sup.6 is H or 1-6C alkyl, R.sup.5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.5 and R.sup.6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R.sup.2 is hydrogen and R.sup.1 is hydrogen or 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C arylalkyl or 7-11C aroyl, the aryl, arylalkyl and aroyl radicals being optionally substituted, ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene or a 1-8C alkylene into which is optionally inserted one or two groups; D is oxygen or sulphur; R.sup.3, R.sup.4 and R.sup.5 are hydrogen or a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及酒精衍生物，它们是组胺H-2拮抗剂并且抑制胃酸分泌。根据本发明，提供了化学式I的胍衍生物：其中R.sup.1和R.sup.2，相同或不同，是氢或1-10C烷基，3-8C环烷基或4-14C环烷基烷基，每个烷基，环烷基或环烷基烷基可选择携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个是卤素取代的，或者R.sup.2是氢而R.sup.1是R.sup.5--E--W--，其中W是可选择通过1或2个1-4C烷基取代的2-6C烷基，E是O、S、SO、SO.sub.2或NR.sup.6，其中R.sup.6是H或1-6C烷基，R.sup.5是H或1-6C烷基，可选择通过1或2个1-4C烷基取代，或者R.sup.5和R.sup.6结合形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环，或者R.sup.2是氢而R.sup.1是氢或1-10C烷基，3-8C环烷基，4-14C环烷基烷基，3-6C烯基，3-6C炔基，1-6C醇酰基，6-10C芳基，7-11C芳基烷基或7-11C酰基，芳基、芳基烷基和酰基基团可选择取代，环X是规范中定义的杂环，A是苯基或5-7C环烷基或可选择插入一到两个基团的1-8C烷基，D是氧或硫，R.sup.3、R.sup.4和R.sup.5是氢或规范中描述的多种基团，以及其药用可接受酸盐。同时描述了制造工艺和药用组合物。
• Heterocyclic derivatives
  申请人：Imperial Chemical Industries PLC

  公开号：US04795755A1

  公开（公告）日：1989-01-03

  This invention relates to heterocyclic derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I: ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen-substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.5 -E-W- in which W is 2-6 alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O,S,SO,SO.sub.2 or NR.sup.6 in which R.sup.6 is H or 1-6C alkyl, R.sup.5 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.5 and R.sup.6 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8C alkylene into which is optionally inserted one or two groups; and R.sup.3 and R.sup.4 are a variety of radicals described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及异噁唑衍生物，它们是组胺H-2拮抗剂，能抑制胃酸分泌。根据本发明，提供了一种式I的胍基衍生物：##STR1## 其中R.sup.1和R.sup.2，相同或不同，为氢或1-10C烷基，3-8C环烷基，4-14C环烷基烷基，每个烷基、环烷基或环烷基烷基可选地携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个是卤素取代的，或者R.sup.2是氢而R.sup.1是R.sup.5-E-W-，其中W是2-6烷基烯，可选地被1或2个1-4C烷基取代，E是O、S、SO、SO.sub.2或NR.sup.6，其中R.sup.6是H或1-6C烷基，R.sup.5是H或1-6C烷基，可选地被1或2个1-4C烷基取代，或者R.sup.5和R.sup.6连接形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环；环X是规范中定义的杂环；A是苯基或5-7C环烷基，或者一个可选地插入一到两个基团的1-8C烷基；R.sup.3和R.sup.4是规范中描述的各种基团；以及其药用可接受的酸盐。还描述了制造工艺和药物组合物。
• Bicyclic guanidines
  申请人：Imperial Chemical Industries PLC

  公开号：US04463005A1

  公开（公告）日：1984-07-31

  The invention relates to bicyclic derivatives which are histamine H-2 antagonists and which inhibit gastric acid secretion. According to the invention there is provided a guanidine derivative of the formula I: ##STR1## in which R.sup.1 and R.sup.2, same or different, are hydrogen or 1-10C alkyl, 3-8C cycloalkyl or 4-14C cycloalkylalkyl, each alkyl, cycloalkyl or cycloalkylalkyl optionally carrying one or more F, Cl or Br atoms, provided that one of R.sup.1 and R.sup.2 is halogen substituted, or R.sup.2 is hydrogen and R.sup.1 is R.sup.3 -E-W in which W is 2-6C alkylene optionally substituted by 1 or 2 1-4C alkyls, E is O, S, SO, SO.sub.2 or NR.sup.4 in which R.sup.4 is H or 1-6C alkyl, R.sup.3 is H or 1-6C alkyl optionally substituted by 1 or 2 1-4C alkyls, or R.sup.3 and R.sup.4 are joined to form a pyrrolidine, piperidine, morpholine, piperazine or N-methylpiperazine ring, or R.sup.2 is H and R.sup.1 is H, 1-10C alkyl, 3-8C cycloalkyl, 4-14C cycloalkylalkyl, 3-6C alkenyl, 3-6C alkynyl, 1-6C alkanoyl, 6-10C aryl, 7-11C aralkyl or 7-11C aroyl; ring X is a heterocyclic ring as defined in the specification; A is phenylene or 5-7C cycloalkylene, or a 1-8 C alkylene into which is optionally inserted one or two groups; ring Y is a heterocyclic ring described in the specification: and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  该发明涉及一类双环衍生物，它们是组织胺H-2受体拮抗剂，并且能够抑制胃酸分泌。根据该发明，提供了一种具有以下式I的胍基衍生物：##STR1## 其中R.sup.1和R.sup.2，相同或不同，为氢或1-10C烷基，3-8C环烷基或4-14C环烷基烷基，每个烷基、环烷基或环烷基烷基可选地携带一个或多个F、Cl或Br原子，前提是R.sup.1和R.sup.2中的一个被卤素取代，或者R.sup.2为氢且R.sup.1为R.sup.3-E-W，其中W为2-6C烷基烯，可选地取代1或2个1-4C烷基，E为O、S、SO、SO.sub.2或NR.sup.4，其中R.sup.4为H或1-6C烷基，R.sup.3为H或1-6C烷基，可选地取代1或2个1-4C烷基，或者R.sup.3和R.sup.4连接形成吡咯烷、哌啶、吗啉、哌嗪或N-甲基哌嗪环，或者R.sup.2为H且R.sup.1为H、1-10C烷基、3-8C环烷基、4-14C环烷基烷基、3-6C烯基、3-6C炔基、1-6C烷酰基、6-10C芳基、7-11C芳基烷基或7-11C芳酰基；环X为规范中定义的杂环；A为苯环或5-7C环烷基，或者可选地插入一到两个基团的1-8C烷基；环Y为规范中描述的杂环；以及其药用可接受的酸盐。还描述了制药过程和制药组合物。
• Haloguanidine compounds, pharmaceutical compositions and methods of use
  申请人：ICI Americas Inc.

  公开号：US04362728A1

  公开（公告）日：1982-12-07

  Compounds useful for inhibiting gastric acid secretion and for the treatment of peptic ulcers caused or exacerbated by gastric acidity having the following formula (I): ##STR1## in which R.sup.1 and R.sup.2, are H, C.sub.1-10 alkyl, C.sub.3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C.sub.1-6 and the cycloalkyl part is C.sub.3-8, each of the alkyl, cycloalkyl and cycloalkylalkyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R.sup.1 and R.sup.2 is a halogen substituted alkyl, cycloalkyl or cycloalkylalkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; and X, m, Y, n and R.sup.3 are as described in the specification; and the pharmaceutically-acceptable acid-addition salts thereof. Processes for producing compounds of formula (I), pharmaceutical compositions containing them, methods of utilizing such compositions and intermediates useful for synthesizing compounds of formula (I) are also described.

  具有以下公式（I）的化合物，用于抑制胃酸分泌和治疗由胃酸引起或加重的消化性溃疡：##STR1## 其中R.sup.1和R.sup.2为H、C.sub.1-10烷基、C.sub.3-8环烷基或环烷基烷基，其中烷基部分为C.sub.1-6，环烷基部分为C.sub.3-8，每个烷基、环烷基和环烷基烷基可选择地被F、Cl和Br中的一个或多个卤素取代，前提是R.sup.1和R.sup.2中至少有一个是被卤素取代的烷基、环烷基或环烷基烷基，并且直接连接到氮的碳上没有卤素取代基；X、m、Y、n和R.sup.3如说明书中所述；以及其药学上可接受的酸加成盐。还描述了制备公式（I）化合物的过程，含有它们的制药组合物，使用这种组合物的方法以及用于合成公式（I）化合物的中间体。
• Guanidine derivatives, processes for their manufacture and pharmaceutical compositions containing them
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0030092A1

  公开（公告）日：1981-06-10

  The invention relates to a guanidine of the formula:- in which R1 and R2 are H, Ci-io alkyl, C3-8 cycloalkyl or cycloalkylalkyl in which the alkyl part is C1-6 and the cycloalkyl part is C3-8, each of the alkyl, cycloalkyl and cycloalkylal- kyls being optionally substituted by one or more halogens selected from F, Cl and Br, provided that at least one of R' and R' is a halogen substituted alkyl, cycloalkyl or cycloalkyl-alkyl and provided that there is no halogen substituent on the carbon directly attached to the nitrogen; ring X is phenyl carrying 1 or 2 optional substitutents or a 5- or 6-membered heterocyclic aromatic ring containing 1, 2 or 3 hetero atoms selected from 0, N and S, which heterocyclic ring may, carry a single optional substituent selected from F, Cl, Br, I, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, trifluoromethyl, hydroxy and amino; Y is 0, S, a direct bond, methylene, vinylene, SO or NR4 in which R4 is H or C1-6 alkyl; m is 0 to 4 and n is 1 to 5, provided that when Y is 0, SO or NR4, n is 2 to 5; R3 has various significances; and the pharmaceutically-acceptable acid-addition salts thereof. Manufacturing processes and pharmaceutical compositions are also described.

  本发明涉及一种胍，其式如下：- 其中 R1 和 R2 为 H、Ci-io 烷基、C3-8 环烷基或环烷基(其中烷基部分为 C1-6，环烷基部分为 C3-8)，每个烷基、环烷基和环烷基可任选被选自 F、Cl 和 Br 的一种或多种卤素取代，条件是 R' 和 R' 中至少有一个是被卤素取代的烷基、环烷基或环烷基烷基，且与氮直接相连的碳上没有卤素取代基； 环 X 是带有 1 或 2 个任选取代基的苯基，或含有 1、2 或 3 个选自 0、N 和 S 的杂原子的 5 或 6 元杂环芳香环，该杂环可带有 1 个选自 F、Cl、Br、I、C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、三氟甲基、羟基和氨基的任选取代基； Y为0、S、直接键、亚甲基、亚乙烯基、SO或NR4，其中R4为H或C1-6烷基；m为0至4，n为1至5，但当Y为0、SO或NR4时，n为2至5；R3具有各种意义；及其药学上可接受的酸加成盐。 此外，还描述了制造工艺和药物组合物。